

ABILIFY ASIMTUFII - (720MG/2.4ML, 960MG/3.2ML)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | ARIPIPRAZOLE | Innovator | Otsuka |
| Dosage | 720MG/2.4ML, 960MG/3.2ML | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | ABILIFY ASIMTUFII is an atypical antipsychotic indicated: • for the treatment of schizophrenia in adults • as maintenance monotherapy treatment of bipolar I disorder in adults | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.